Xeris Biopharma Holdings (XERS) Net Cash Flow (2020 - 2026)

Xeris Biopharma Holdings has reported Net Cash Flow for 7 years, with the latest figure at $708000.0 in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 105.37% year-over-year to $708000.0; the trailing twelve-month figure through Mar 2026 stood at $53.2 million (up 1322.61% YoY), and the FY2025 full-year result was $39.3 million, up 866.07% from the prior year.
• Net Cash Flow for Q1 2026 stood at $708000.0, down from $19.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $42.2 million in Q4 2022, with the low at -$71.0 million in Q1 2023.
• Historically, Net Cash Flow has averaged $2.9 million across 5 years, with a median of $708000.0 in 2026.
• Annual changes were most pronounced in 2023 — Net Cash Flow sank 294.47% — and 2024, when it jumped 5751.85%.
• Xeris Biopharma Holdings' Net Cash Flow stood at $42.2 million in 2022, then tumbled by 49.99% to $21.1 million in 2023, then plunged by 41.3% to $12.4 million in 2024, then soared by 56.95% to $19.4 million in 2025, then tumbled by 96.36% to $708000.0 in 2026.
• The last three Net Cash Flow figures came in at $708000.0 (Q1 2026), $19.4 million (Q4 2025), and $32.2 million (Q3 2025), per Business Quant data.